Safety and Activity of IMAB362 in Combination With Zoledronic Acid and Interleukin-2 in CLDN18.2-positive Gastric Cancer
Status:
Completed
Trial end date:
2014-10-13
Target enrollment:
Participant gender:
Summary
The purpose of the trial is to assess the immunological effects and their kinetics, the
safety and activity of IMAB362 plus Zoledronic acid with/without low to intermediate doses of
Interleukin-2 in subjects with advanced gastroesophageal cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Astellas Pharma Global Development, Inc. Ganymed Pharmaceuticals AG